Several smaller biotechnology companies are also attracting attention from larger pharmaceutical players, including Viking Therapeutics and Zealand Pharma, whose programmes are widely viewed as potential licensing or acquisition targets
[0004] The formation of peptides is nothing more than the application of the amide synthesis reaction
Both are injectable treatments with legitimate medical applications, but sermorelin therapy and semaglutide target entirely different hormonal systems, produce different outcomes, and are suited to different patient profiles
Further studies on the effects of semaglutide on alcohol use are needed to determine whether the findings could be replicated in humans
Smaller Biotechs and Collaborators: Companies like Zealand Pharma, Glycadia, and others have GLP-1 analogs or co-agonists in early trials, often in partnership with larger pharma (e.g., Novo Nordisk collaboration with Zealand)